PBI
65
5
GILD
49
2
D
45
5
ORCL
67
2
URBN
42
4
TXT
52
4
AEP
53
2
COP
54
-2
AA
60
9
EW
39
2
XEL
69
2
MAS
56
5
CMS
60
2
TROW
51
3
ACN
49
2
SLG
66
2
CB
51
3
NKE
30
2
XRX
41
6
EXPD
45
8
PBI
65
5
GILD
49
2
D
45
5
ORCL
67
2
URBN
42
4
TXT
52
4
AEP
53
2
COP
54
-2
AA
60
9
EW
39
2
XEL
69
2
MAS
56
5
CMS
60
2
TROW
51
3
ACN
49
2
SLG
66
2
CB
51
3
NKE
30
2
XRX
41
6
EXPD
45
8
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
33

PTGX
Protagonist Therapeutics

Last Price:
44.66
Seasonality Move:
11.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Access The Stock Grader Trading Tool From "The King Of Quants"

More details here...

Protagonist Therapeutics Price Quote

$44.66
+3.01 (+7.23%)
(Updated: November 22, 2024 at 12:25 PM ET)

Protagonist Therapeutics Key Stats

Sell
33
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$40.72 - $43.38
52-week range:
$16.80 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.95
P/B ratio:
4.67%
Volume:
936.4K
Avg. volume:
655.9K
1-year change:
139.92%
Market cap:
$2.5B
Revenue:
$60M
EPS:
$2.66

How Much Does Protagonist Therapeutics Make?

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $230.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $22.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$352M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 37.59%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 33.69%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 37.59%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.89%
Revenue: 0% 157.93%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 54.38
Upside from Last Price: 30.55%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    109.4M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders